As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer, the biomarker-driven Lung Cancer Master Protocol, or Lung-MAP, has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.
Paradigm Health announced on March 20 the appointment of Karen E. Knudsen to its board of directors, alongside the upcoming launch of its eSource clinical trial data application.
